These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 29249233

  • 1. Abatacept efficacy in steroid-resistant minimal-change disease revealed by the speed of proteinuria reduction after the start of abatacept
.
    Dado D, Parikh S, Ayoub I, Rovin B, Nadasdy T, Hebert L.
    Clin Nephrol; 2018 May; 89(5):376-380. PubMed ID: 29249233
    [Abstract] [Full Text] [Related]

  • 2. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.
    Garin EH, Reiser J, Cara-Fuentes G, Wei C, Matar D, Wang H, Alachkar N, Johnson RJ.
    Pediatr Nephrol; 2015 Mar; 30(3):469-77. PubMed ID: 25239302
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: A systematic review of case reports, case series, and observational studies
.
    Hansrivijit P, Puthenpura MM, Ghahramani N.
    Clin Nephrol; 2020 Sep; 94(3):117-126. PubMed ID: 32589135
    [Abstract] [Full Text] [Related]

  • 4. A partial response to abatacept in a patient with steroid resistant focal segmental glomerulosclerosis.
    Soyaltın E, Demir BK, Alparslan C, Çamlar SA, Alaygut D, Yavaşcan Ö, Mutlubaş F.
    Turk J Pediatr; 2020 Sep; 62(4):663-667. PubMed ID: 32779421
    [Abstract] [Full Text] [Related]

  • 5. Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis.
    Siligato R, Cernaro V, Nardi C, De Gregorio F, Gembillo G, Costantino G, Conti G, Buemi M, Santoro D.
    Expert Opin Investig Drugs; 2018 Nov; 27(11):839-879. PubMed ID: 30360670
    [Abstract] [Full Text] [Related]

  • 6. The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: a multicenter study in Korea.
    Lee HY, Kim HS, Kang CM, Kim SG, Kim MJ.
    Clin Nephrol; 1995 Jun; 43(6):375-81. PubMed ID: 7554521
    [Abstract] [Full Text] [Related]

  • 7. Baseline characteristics and long-term outcomes of steroid-resistant nephrotic syndrome in children: impact of initial kidney histology.
    Watanabe Y, Fujinaga S, Endo A, Endo S, Nakagawa M, Sakuraya K.
    Pediatr Nephrol; 2020 Dec; 35(12):2377-2381. PubMed ID: 32964318
    [Abstract] [Full Text] [Related]

  • 8. Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study.
    Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Takeda A, Tsukamoto T, Uchida S, Tsuruya K, Shoji T, Hayashi H, Akai Y, Fukunaga M, Konta T, Nishio S, Goto S, Tamai H, Nagai K, Katafuchi R, Masutani K, Wada T, Nishino T, Shirasaki A, Sobajima H, Nitta K, Yamagata K, Kazama JJ, Hiromura K, Yasuda H, Mizutani M, Akahori T, Naruse T, Hiramatsu T, Morozumi K, Mimura T, Saka Y, Ishimura E, Hasegawa H, Ichikawa D, Shigematsu T, Sato H, Narita I, Isaka Y, Japan Nephrotic Syndrome Cohort Study investigators.
    J Nephrol; 2022 May; 35(4):1135-1144. PubMed ID: 35366214
    [Abstract] [Full Text] [Related]

  • 9. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
    Li X, Li H, Ye H, Li Q, He X, Zhang X, Chen Y, Han F, He Q, Wang H, Chen J.
    Am J Kidney Dis; 2009 Jul; 54(1):51-8. PubMed ID: 19406543
    [Abstract] [Full Text] [Related]

  • 10. Minimal change disease and focal segmental glomerulosclerosis in adults: response to steroids and risk of renal failure.
    Moura LR, Franco MF, Kirsztajn GM.
    J Bras Nefrol; 2015 Jul; 37(4):475-80. PubMed ID: 26648497
    [Abstract] [Full Text] [Related]

  • 11. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.
    Bomback AS, Canetta PA, Beck LH, Ayalon R, Radhakrishnan J, Appel GB.
    Am J Nephrol; 2012 Jul; 36(1):58-67. PubMed ID: 22722778
    [Abstract] [Full Text] [Related]

  • 12. Abatacept experience in steroid and rituximab-resistant focal segmental glomerulosclerosis.
    Jayaraman VK, Thomas M.
    BMJ Case Rep; 2016 Feb 17; 2016():. PubMed ID: 26887886
    [Abstract] [Full Text] [Related]

  • 13. The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series.
    Maas RJ, Deegens JK, Beukhof JR, Reichert LJ, Ten Dam MA, Beutler JJ, van den Wall Bake AWL, Rensma PL, Konings CJ, Geerse DA, Feith GW, Van Kuijk WH, Wetzels JF.
    Am J Kidney Dis; 2017 May 17; 69(5):637-646. PubMed ID: 28089478
    [Abstract] [Full Text] [Related]

  • 14. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum.
    Stokes MB, Markowitz GS, Lin J, Valeri AM, D'Agati VD.
    Kidney Int; 2004 May 17; 65(5):1690-702. PubMed ID: 15086908
    [Abstract] [Full Text] [Related]

  • 15. Tacrolimus improves proteinuria remission in adults with cyclosporine A-resistant or -dependent minimal change disease.
    Xu D, Gao X, Bian R, Mei C, Xu C.
    Nephrology (Carlton); 2017 Mar 17; 22(3):251-256. PubMed ID: 28035723
    [Abstract] [Full Text] [Related]

  • 16. Long-term ciclosporine A treatment in adults with minimal change nephrotic syndrome or focal segmental glomerulosclerosis.
    Ittel TH, Clasen W, Fuhs M, Kindler J, Mihatsch MJ, Sieberth HG.
    Clin Nephrol; 1995 Sep 17; 44(3):156-62. PubMed ID: 8556831
    [Abstract] [Full Text] [Related]

  • 17. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations.
    Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, Ponticelli C, Saito T, Choukroun G, Nachman P, Praga M, Yoshikawa N.
    Kidney Int; 2007 Dec 17; 72(12):1429-47. PubMed ID: 17898700
    [Abstract] [Full Text] [Related]

  • 18. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
    Hansrivijit P, Cheungpasitporn W, Thongprayoon C, Ghahramani N.
    BMC Nephrol; 2020 Apr 15; 21(1):134. PubMed ID: 32293308
    [Abstract] [Full Text] [Related]

  • 19. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS).
    Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takeda A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsuruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Nagai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Nishino T, Sobajima H, Tanaka S, Akahori T, Ito T, Terada Y, Katafuchi R, Fujimoto S, Okada H, Ishimura E, Kazama JJ, Hiromura K, Mimura T, Suzuki S, Saka Y, Sofue T, Suzuki Y, Shibagaki Y, Kitagawa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y.
    Clin Exp Nephrol; 2020 Jun 15; 24(6):526-540. PubMed ID: 32146646
    [Abstract] [Full Text] [Related]

  • 20. Unexplained severe acute kidney injury with rapid recovery of kidney function 11 months later after the start of high-dose steroid therapy.
    Roncone D, Rovin B, Falk R, Nicely C, Nadasdy T, Parikh S, Hebert LA.
    Clin Nephrol; 2014 Aug 15; 82(2):138-43. PubMed ID: 23380388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.